These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11231516)

  • 1. Biotech industry faces new bottleneck.
    Garber K
    Nat Biotechnol; 2001 Mar; 19(3):184-5. PubMed ID: 11231516
    [No Abstract]   [Full Text] [Related]  

  • 2. New biotech hubs may emerge as industry matures.
    Basu P
    Nat Biotechnol; 2003 Oct; 21(10):1123. PubMed ID: 14520385
    [No Abstract]   [Full Text] [Related]  

  • 3. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 5. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 6. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 7. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 8. What's fueling the biotech engine-2007.
    Aggarwal S
    Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
    [No Abstract]   [Full Text] [Related]  

  • 9. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 11. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 13. The lengthening handshake.
    Osborne R
    Nat Biotechnol; 2010 Mar; 28(3):197-9. PubMed ID: 20212476
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 15. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 16. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 17. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 18. Hatteras rounds up $90 million to lead biotech rebound in North Carolina.
    Erickson D
    Nat Biotechnol; 2015 Nov; 33(11):1121-2. PubMed ID: 26544128
    [No Abstract]   [Full Text] [Related]  

  • 19. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 20. Barnyard biotech--lame duck or golden goose?
    Powell K
    Nat Biotechnol; 2003 Sep; 21(9):965-7. PubMed ID: 12949546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.